ArticlePsychopharmacology2026
Relationships among peri-traumatic circulating endocannabinoids and long-term, negative outcomes following traumatic injury.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- EBPS2023 special issue: Stress, trauma and cannabinoids.Psychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
rationaleTraumatically injured individuals can develop chronic negative psychological sequelae. Improved understanding of contributing, peri-traumatic risk factors is essential to reduce the risk of these consequences. Previous studies have found that peri-traumatic, circulating endocannabinoid concentrations are positively associated with development of post-traumatic stress disorder (PTSD), chronic pain and depression months later, particularly in members of racial/ethnic groups that have been historically marginalized.
objectivesThis replication study examined relationships among peri-trauma serum endocannabinoid concentrations and long-term consequences in a cohort comprised primarily of individuals from marginalized racial and ethnic groups.
methodsParticipants (n = 100; 81% from marginalized racial and ethnic groups) were traumatically injured adults presenting to the ED of an urban tertiary care hospital. Endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) were measured in serum collected within days (peri-trauma) and 6-10 months following injury (follow-up). Assessments, including PTSD, depression, pain and quality of life were completed. Statistical approaches, including multivariate, hierarchical regressions, were used to determine associations among serum endocannabinoid concentrations and long-term outcomes.
resultsAlthough it did not survive correction for multiple comparisons, peri-trauma serum 2-AG concentrations. Peri-trauma serum 2-AG concentrations were also positively associated with PTSD, pain severity, and functional engagement scores at follow-up. There were no significant associations between circulating 2-AG or AEA and depression.
conclusionsThese findings generally replicate earlier studies demonstrating that serum 2-AG concentrations are biomarkers of risk for PTSD and pain and uncover an additional association with poor functional quality of life. Further studies are needed to determine the underlying mechanisms of these relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.